Research programme: small molecule therapeutics - Suzhou NeuPharma
Alternative Names: RX 101Latest Information Update: 28 Jul 2019
At a glance
- Originator Suzhou NeuPharma
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neurodegenerative disorders
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Neurodegenerative-disorders in China
- 10 Jun 2015 Early research in Neurodegenerative disorders in China (unspecified route)